274682-80-3

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 3-(thiocarbamoyl)piperidine-1-carboxylate is utilized as a key intermediate in organic synthesis for the creation of a variety of organic compounds. Its unique structural features facilitate the formation of new chemical entities through various synthetic routes.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 3-(thiocarbamoyl)piperidine-1-carboxylate is employed as a precursor in the synthesis of pharmaceuticals. Its incorporation into drug molecules can contribute to the development of novel therapeutic agents with potential medicinal properties.
Used in Drug Production:
As an intermediate in drug production, tert-butyl 3-(thiocarbamoyl)piperidine-1-carboxylate plays a crucial role in the manufacturing process of certain drugs. Its presence in the synthesis pathway can enhance the efficiency and effectiveness of drug manufacturing.
Used in Pharmacological Research:
Tert-butyl 3-(thiocarbamoyl)piperidine-1-carboxylate is used as a research tool in pharmacology to explore its biological activity. Its potential as a bioactive molecule makes it a candidate for studies aimed at understanding its interactions with biological systems and its role in drug discovery.
Used in Drug Discovery:
In the realm of drug discovery, tert-butyl 3-(thiocarbamoyl)piperidine-1-carboxylate is leveraged for its potential to contribute to the development of new drugs. Its unique chemical structure and properties make it a valuable component in the search for innovative therapeutic solutions.

InChI:InChI=1/C11H20N2O2S/c1-11(2,3)15-10(14)13-6-4-5-8(7-13)9(12)16/h8H,4-7H2,1-3H3,(H2,12,16)

Upstream product

• 91419-49-7 tert-butyl 3-carbamoylpiperidine-1-carboxylate 
• 4138-26-5 nipecotamide 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1037793-58-0 5-ethyl-2-{3-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidin-1-yl}pyrimidine 
• 1037793-55-7 3-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1271809-14-3 C₁₅H₁₈N₄OS 
• 1271809-12-1 C₂₀H₂₆N₄O₃S 
• 1271802-74-4 1-(2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)thiazol-5-yl)-3-phenylurea 
• 1271808-87-7 C₂₀H₂₆N₄O₃S 
• 1271802-37-9 1-(2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)thiazol-4-yl)-3-phenylurea 
• 1192248-02-4 tert-Butyl 3-[4-(ethoxycarbonyl)-1,3-thiazol-2-yl]piperidine-1-carboxylate 
• 162167-97-7 tert-butyl 3-(aminomethyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine, receptors and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans. The compositions comprising a muscarinic agonist or a pharma.ceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

BRUTON'S TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions.

Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors

Truncation of potent and selective dibasic inhibitors afforded monocharged inhibitors of human mast-cell tryptase. Using two classes of analogues as lead structures, several monocharged derivatives were identified with Ki values ranging from 0.